Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

During a Senate HELP Committee hearing, RFK Jr. stated that President Trump is dedicated to bringing drug manufacturing "back ...

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Is Eli Lilly a good stock to buy on the dip ... The Food and Drug Administration (FDA) allows compounding pharmacies to step ...

Purdue partners with Eli Lilly and Merck to launch the Young Institute Pharmaceutical Manufacturing Consortium, focusing on sterile injectables.

Eli Lilly’s (LLY ... causing persistent shortages. Key Points: Manufacturing constraints hamper Lilly and Novo Nordisk’s ability to meet drug demand. 2025 revenue guidance of $58–$61 ...

Eli Lilly unexpectedly lowered its full ... Lilly noted that it has spent aggressively to add more manufacturing capacity for its GLP-1 drugs, spending $23 billion over the last three years.